Tanios S. Bekaii-Saab, MD Phoenix, Arizona
Editorial Board
Tanios S. Bekaii-Saab, M.D., conducts clinical and translational research focused on developing anti-cancer agents for patients with gastrointestinal cancers. Dr. Bekaii-Saab collaborates extensively with various scientists and industry partners to design and execute innovative clinical trials, including many first-in-human studies. He also leads the Mayo Clinic-supported cancer research consortium Academic and Community Cancer Research United (ACCRU) and is one of the leading clinician-scientists in the Alliance for Clinical Trials in Oncology, a National Cancer Institute (NCI)-supported cooperative research group.
Dr. Bekaii-Saab’s research includes a large focus on the incorporation of agents that target the multiple facets of cancer, including genetic and epigenetic drivers, as well as the feeding microenvironment and the immune milieu. His work includes two recent discoveries as co-inventor of a molecule that targets cancer-related cachexia (AR-42) and an anti-PD-1 vaccine. His research has also led to the launch of a number of phase II and III clinical trials, including a recent trial with a cancer stem cell inhibitor (napabucasin) in pancreatic cancer, the development of an inhibitor of fibroblast growth factor receptor (FGFR) fusion genes in bile duct cancers, and a contribution to the pivotal study that led to the regulatory approval of nanoliposomal irinotecan for treating pancreatic cancer.